ADVERTISEMENT
Biosimilars Provide Lower-Cost Alternatives to Biologics Used in Cancer Care
Biosimilars may provide lower-cost alternatives to biologics used in cancer care, according to findings from a recent review published in JCO Oncology Practice (2022; OP2100771. doi:10.1200/OP.21.00771)
“The increased number and expanded utilization of biosimilars raise important considerations for their safe and appropriate use in oncology practice,” wrote Zeina Nahleh, MD, Cleveland Clinic Florida, Weston, FL, and colleagues
In this report, Dr Nahleh and colleagues aimed to provide an update on currently approved oncology biosimilars and identify knowledge gaps in the management of patients with cancer.
Medical literature was reviewed by a panel of experts to summarize currently approved biosimilar therapeutics for cancer treatment or supportive care in the United States.
Since 2015, 17 cancer or cancer-related biosimilar products have been approved by the US Food and Drug Administration.
“ASCO supports that biosimilars and reference products are considered equally efficacious for the purpose of inclusion in ASCO clinical practice guideline recommendations,” wrote Dr Nahleh and colleagues.
“The use of biosimilars might provide competitive, lower-cost alternatives to biologics used in cancer care, and specific mention in ASCO guidelines and other evidence products is supported where appropriate,” concluded Dr Nahleh and colleagues.
